- Home
- DMN vs AIM Comparison
DMN vs AIM Comparison
Compare DMN & AIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMN
- AIM
- Stock Information
- Founded
- DMN 2020
- AIM 1966
- Country
- DMN Canada
- AIM United States
- Employees
- DMN N/A
- AIM N/A
- Industry
- DMN
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DMN
- AIM Health Care
- Exchange
- DMN NYSE
- AIM Nasdaq
- Market Cap
- DMN 19.4M
- AIM 15.9M
- IPO Year
- DMN N/A
- AIM N/A
- Fundamental
- Price
- DMN $0.73
- AIM $0.21
- Analyst Decision
- DMN
- AIM Strong Buy
- Analyst Count
- DMN 0
- AIM 2
- Target Price
- DMN N/A
- AIM $2.75
- AVG Volume (30 Days)
- DMN 442.1K
- AIM 672.1K
- Earning Date
- DMN 02-15-2025
- AIM 11-15-2024
- Dividend Yield
- DMN N/A
- AIM N/A
- EPS Growth
- DMN N/A
- AIM N/A
- EPS
- DMN N/A
- AIM N/A
- Revenue
- DMN N/A
- AIM $190,000.00
- Revenue This Year
- DMN N/A
- AIM N/A
- Revenue Next Year
- DMN N/A
- AIM $1,693.10
- P/E Ratio
- DMN N/A
- AIM N/A
- Revenue Growth
- DMN N/A
- AIM N/A
- 52 Week Low
- DMN $0.51
- AIM $0.16
- 52 Week High
- DMN $4.95
- AIM $0.62
- Technical
- Relative Strength Index (RSI)
- DMN N/A
- AIM 50.86
- Support Level
- DMN N/A
- AIM $0.19
- Resistance Level
- DMN N/A
- AIM $0.23
- Average True Range (ATR)
- DMN 0.00
- AIM 0.02
- MACD
- DMN 0.00
- AIM -0.00
- Stochastic Oscillator
- DMN 0.00
- AIM 48.29
About DMN DAMON INC
Damon Inc is a motorcycle manufacturing company that aims to transform the motorcycle industry by building a smart and technologically advanced motorcycle. Damon is developing technology and investing in capabilities to lead the industry in the transformation of the high-performance electric motorcycle market. It is introducing existing enthusiasts to high-performance electric products while bringing new riders to the motorcycle community with first-of-its-kind advances in zero-emissions motorcycle performance, safety, connectivity and AI.
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.